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Abstract Gout affects 1% to 2% of the population, and the
prevalence is increasing due to changes in diet and the
ageing of the population. Its development and risk factors
have been explored frequently, and recommendations for the
diagnosis and management of gout implemented. Neverthe-
less, there is a lack of knowledge regarding the long-term
impact on gouty patients. This systematic review therefore
evaluates the association between gout and all-cause as well
as cardiovascular mortality. A systematic literature search
was performed, and seven long-term studies were ultimately
analyzed. Six of them used multivariate regressions to as-
sess the adjusted mortality ratio in gouty patients with
reference to patients without the disorder. Despite differ-
ences in study designs, study populations, and definitions
of gout, the results were consistent: There was an indepen-
dent association between gout and all-cause as well as
cardiovascular mortality. Knowing that patients with gout
are at risk emphasizes the need for adequate care.
Keywords Gout.Mortality.All-causemortality.
Cardiovascularmortality.Systematic review.Association.
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Introduction
Gout is a common disease with increasing prevalence. Its
manifestation, progression, adequate therapeutic interventions,
and related comorbidities are therefore frequently discussed
in the literature. Less attention is paid to the question of
whether gout has an impact on mortality. However, this
long-term outcome is relevant not only for the patient.
New light should also be shed on the significance of this
disease and consequently on the treatment and care of
gouty patients, as these often remain suboptimal [1].
Gout is a crystal deposition disease in which renal
elimination of uric acid is insufficient. The increased uric
acid level can lead to the formation of monosodium urate
crystals in synovial fluid or soft tissues. This results in
painful inflammation of the joints, which is why the
disorder is also known as inflammatory arthritis [1, 2].
The typical initial presentation of gout is podagra [3].
Gout is characterized by recurrent acute episodes and can
become a chronic condition [3–5].
The prevalence of gout has increased in recent decades.
This might be the result of a changing diet and an ageing
population [2, 3]. Despite methodologic challenges, the
international prevalence is estimated at up to 1% to 2%
[1, 6, 7]. Menaremorelikelytobeaffectedthanwomen,and
the prevalence increases with age [1, 8].
In 2006, the European League Against Rheumatism
(EULAR) developed evidence-based recommendations for
the diagnosis and management of gout [1, 9], according
to which the disease may be diagnosed by monosodium
urate crystals in synovial fluid, podagra, or tophus, while
a raised serum urate level alone is not specific to gout
[1]. Risk factors for the development of gout are diet [2, 5];
genetic predisposition [2, 4]; hyperuricemia [4, 10]; and
comorbidities such as diabetes, hypertension, obesity, heart
failure, and renal insufficiency [2, 6, 11].
The managementofgoutaimsatlowering and maintaining
serum urate levels below the saturation point (6.8 mg/dL, or
408 μmol/L). This helps to dissolve existing monosodium
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DOI 10.1007/s11926-011-0234-2urate crystals and to prevent further crystals from forming
[1, 9]. In addition, special diets, weight reduction, and
reduced alcohol consumption are among the nonpharma-
cologic interventions [4].
The objective of this review is to scrutinize in a
systematic manner whether there is an association between
gout and all-cause or cardiovascular mortality. Despite
neither the management of gout nor economic aspects
being considered, this systematic review is intended to
impact on recurrent discussion about the management of
gout. Furthermore, knowledge about the association of
gout and mortality may underline the need for adequate
care.
Methods
Data Sources
We conducted a systematic literature search of Medline
u n dE M B A S Eu pt oA p r i l2 0 1 1u s i n gas e a r c hs t r a t e g y
combining the Medical Subject Headings (MeSH terms)
and keywords in the titles/abstracts. The search string
consisted of keywords referring to the medical indication
gout linked by the Boolean operator “AND” to terms
associated with the outcomes of all-cause mortality or
cardiovascular mortality. Publications in English, French,
and German were included, whereas studies on animals
were excluded. In addition, we performed a manual
search of references.
Study Selection
Studies were included in this review if they were non-
interventional trials investigating the association between
gout and all-cause or cardiovascular mortality in patients
with gout compared with the population without this
disease. Gout could be defined by the respective ICD
codes (ICD-9 code 274.x or ICD-10 code M10.x [12, 13])
or diagnosed by a physician in accordance with the
evidence-based EULAR recommendations [1]. The
patient-relevant outcomes considered were all-cause
mortality and cardiovascular mortality (ICD-9 code
390–459, ICD-10 code I00–I99) [12, 13]. Studies ana-
lyzing the association between a single cardiovascular
disease (CVD) (eg, the number of fatal myocardial
infarctions) and gout were therefore excluded because
this systematic review focuses on cardiovascular mortal-
ity as a whole. In addition, studies of the best available
and most feasible evidence were to be included. With
regard to the question posed by this review, the best
evidence would be a retrospective cohort study with a
2b level of evidence [14].
Validity Assessment and Data Abstraction
Two investigators (Lottmann and Chen) independently
scrutinized all identified studies after excluding dupli-
cates. As a first step, the titles and abstracts were inves-
tigated withregardtothe predefinedinclusion criteria, and the
full texts of all potentially relevant studies were evaluated
next. In case of disagreement, consensus was reached by
discussion. The selection process, including the reasons for
exclusion, was documented. Due to the lack of a validat-
ed quality assessment tool for nonrandomized interven-
tions [15], we developed our own checklist [16]. Our
quality checklist was based on the methodologic require-
ments of the German Agency for Health Technology Assess-
ment [17] and on the Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guide-
lines [18]. Finally, the quality of each study included was
assessed and scored. The data from all studies scored
with at least “fair” methodologic quality were subse-
quently collected by one reviewer using a self-
developed data abstraction list.
Results
Study Identification and Selection
The process of the systematic literature search is depicted in
Fig. 1. The number of articles identified, screened, and
excluded, as well as the number of full-texts retrieved and
finally included for data abstraction is delineated. We iden-
tified seven articles as conforming to our inclusion criteria.
All of them analyzed the association between gout and
all-cause mortality (seven studies) as well as cardiovascular
mortality (four studies) as either a primary or secondary
outcome.
The study types varied from retrospective to prospective.
They consisted of cohort studies, surveys, and data analyses.
All these studies, except one [19], analyzed the association
between gout and mortality using multivariate regression
(ie, they calculated hazard ratios [HRs] or risk ratios
[RRs]). In addition, several studies determined the mortality
rate in patients with gout compared with people without this
disease. In this review, we focus on the results of the
regression analyses, as this is the more appropriate way of
obtaining conclusive results.
Patient Characteristics
Patient populations were very heterogeneous in the different
studies, which made comparison challenging. Whereas
two studies included renal transplant populations [20, 21],
another two focused on individuals with coronary heart
196 Curr Rheumatol Rep (2012) 14:195–203disease (CHD) or those who were at risk of this disorder
[22••, 23]. One study analyzed data from US veterans
[19], while another included only data from health pro-
fessionals [24]. An additional study evaluating partici-
pants in a health-screening program in Taiwan was
included. Even if an almost equal sex ratio in the study
population was provided, gout was far more common in
men than in women (90.4% of the patients with gout
were male) [25••]. Furthermore, several studies were
conducted in an older population. Despite this heterogeneity,
each study population was characteristic of gouty patients.
Study populations showed typical comorbidities, age groups,
and male dominance in patients with gout.
The definition of gouty patients varied from study to
study, as did the prevalence of gout in the study population
(range, 2.1%–10.6%). The 1-year mortality rate from all
causes also varied (range, 2.6%–14.3%).
Gout and All-Cause Mortality
Abbott et al. [20] used Medicare claims data of primary
renal transplant patients reported in the United States
Renal Data System (USRDS). The aim of their retrospective
cohort study was to evaluate the implications of new-
onset gout on survival. They determined an increased
risk of mortality (adjusted HR [AHR], 1.26 [95% CI,
1.08–1.47]) in patients developing gout after kidney
transplantation compared with renal transplant patients
without the disorder. Gout diagnosed prior to transplant
was not significantly associated with an increased risk
of mortality (AHR, 1.18 [95% CI, 0.98–1.43]). Their
study indicates an independent association between
new-onset gout after renal transplantation and all-cause
mortality.
One more study evaluated the association between
incident gout in renal transplant patients and mortality using
the USRDS. This study population was treated with dialysis
after the transplantation, and gout was associated with an
increased risk of mortality (AHR, 1.49 [95% CI, 1.43–1.55];
P<0.001)[21].Theresultnotonlyconfirmedtheindependent
association with new-onset gout after renal transplantation
but even determined an elevated mortality risk in kidney
transplant patients treated with dialysis [21] compared with
those without dialysis [20].
Fig. 1 Flow diagram of study
identification and selection.
(Adapted from Khan et al. [16])
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patients with cardiovascular comorbidities was investigated
in a time-matched, nested case-control analysis of a
retrospective cohort study based on the Quebec Universal
HealthInsurancedatabase.Thestudypopulation(age>66years)
had been discharged from the hospital with a primary
diagnosis of heart failure. Death was considered to be
associated with gout if the patient suffered an acute
episode of gout within 60 days before death. Regarding
the gout population, a distinction was made between
three definitions of gout. The risk of all-cause mortality
in patients with any acute gout was significantly increased,
even if adjusted for several CVDs and medications (adjusted
RR [ARR], 1.76 [95% CI, 1.08–2.86]; P00.02). No signifi-
cant association between acute gout and all-cause mortality
was found in patients admitted to the hospital for gout.
However, in patients visiting an emergency department
for a gout flare, gout was again significantly associated
with an increased risk of death from all causes (ARR, 2.10
[95% CI, 1.19–3.70]; P00.01) [22￿￿].
Whether there is an association between gout and all-
cause mortality in men at above average risk of CHD but
without evidence of clinical CVD during the intervention
phase was evaluated in the long-term follow-up of the
MRFIT (Multiple Risk Factor Intervention Trial) study
over 17 years. Again, different definitions of gout were
used: self-reported gout and documented hyperuricemia,
self-reported gout alone, and prescribed gout medication.
Gouty patients based on self-reported gout and docu-
mented hyperuricemia had an increased mortality risk
(AHR, 1.22; P00.009) compared with those patients with
neither gout nor hyperuricemia. The mortality risk in
gouty patients, defined by use of gout-related medicine
(allopurinol, probenecid, or colchicine), was comparable
(AHR, 1.23; P<0.001) [23]. The association between
gout and all-cause mortality was revealed once again,
although hyperuricemia might have biased the result in
one of the analyses.
A further study focused on patients with gout and
cardiovascular comorbidities [24]. In the prospective
Health Professionals Follow-Up Study, which was limited
to male participants, data were acquired via mailed ques-
tionnaires. The authors calculated the adjusted mortality
risk in patients with gout and with CHD, as well as in
gouty patients without CHD comorbidity (in each case
compared with patients without gout but with the
corresponding CHD status). They furthermore evaluated
different definitions of gout: any gout, history of gout,
and newly diagnosed gout. Patients with a history of
gout without CHD had a slightly higher mortality risk
( A R R ,1 . 2 8[ 9 5 %C I ,1 . 1 5 –1.41]) than those with a
history of gout and CHD comorbidity (ARR, 1.25 [95%
CI, 1.09–1.45]). Moreover, an increased mortality risk
was determined in patients with newly diagnosed gout
(ARR, 1.28 [95% CI, 1.13–1.46]); CHD comorbidities
were not reported. In the analysis including any gouty
patients, the mortality risk was slightly lower in the
group without CHD (ARR, 1.25 [95% CI, 1.13–1.38]) than
in the group with CHD (ARR, 1.35 [95% CI, 1.21–1.50])
[24]. This study thus reported an association between
gout and all-cause mortality independent of the CHD
status and not affected by the gout duration.
While all the studies mentioned above included mainly
Caucasians as well as a few black patients, the association
between gout and all-cause mortality was also confirmed in
an Asian population. Data from a health-screening program
in Taiwan were investigated. This analysis revealed an
increased risk of death from all causes in patients with
gout (AHR, 1.46 [95% CI, 1.12–1.91]; P00.005) [25￿￿].
The mortality risk was even higher when a more verifiable
definition of gout was used and the analysis included only
patients with monosodium urate crystals in the synovial fluid
orICDcode274.x,andexcludedthosewithself-reportedgout
(AHR, 1.51 [95% CI, 1.14–1.99]; P00.004).
One study did not calculate an RR to evaluate the
association between gout and all-cause mortality but
accounted for a multivariable-adjusted difference in the
m o r t a l i t yr a t e .B a s e do nam a i l e ds u r v e yt oU Sv e t e r a n s
(99% men), similar mortality rates were determined in
individuals with and without gout (no gout, 2.22% [95% CI,
1.56%–3.15%]; gout, 2.62% [95% CI, 1.60%–4.28%];
difference, 18.47%; P00.230) [19]. Gout therefore did
not have an impact on the mortality rate in this study.
However, conclusions regarding the association between
gout and all-cause mortality should be drawn carefully,
as the statistical methods used differ from those in the
other studies described previously. Detailed figures are
d i s p l a y e di nT a b l e1.
Gout and Cardiovascular Mortality
Besides the described independent association between gout
and all-cause mortality, four of the seven identified studies
evaluated the impact of gout on cardiovascular mortality as
well. All of them revealed that gout is also associated with
an increased risk of cardiovascular mortality; the results are
outlined in detail in Table 1. The cardiovascular mortality
risk in gouty renal transplant patients treated with dialysis
was increased compared with those patients without gout
(AHR, 1.47 [95% CI, 1.26–1.59]). However, this mortality
ratio was slightly lower than the all-cause mortality risk in
the same group [21].
Even in the long-term follow-up study over 17 years,
gout was associated with cardiovascular mortality, but the
risk changed when data were limited to special defini-
tions of gout. Based on self-reported gout and diagnosed
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Curr Rheumatol Rep (2012) 14:195–203 199hyperuricemia, the cardiovascular mortality risk was only
significantly higher when the reference group consisted
of patients with neither gout nor hyperuricemia (AHR, 1.30;
P00.02). The risk was not significantly increased when
compared with patients without gout but potentially with
hyperuricemia. Two sensitivity analyses with gouty
patients defined as 1) using gout medication and 2) having
self-reported gout revealed a nonsignificantly increased risk
of cardiovascular mortality [23].
The independent association between gout and cardio-
vascular mortality was also reported in the Health Profes-
sionals Follow-Up Study. In this case, the cardiovascular
mortality risk in patients with gout was even slightly higher
than the all-cause mortality risk for the same group. Again,
the analysis of risk was carried out for different gout groups,
depending on the duration of illness (history of gout, newly
diagnosed gout, and any gout) and on the CHD status
(history of gout [no CHD]: ARR, 1.38 [95% CI, 1.15–1.66];
history of gout [CHD]: ARR, 1.26 [95% CI, 1.07–1.50];
newly diagnosed gout [CHD not reported]: ARR, 1.31
[95% CI, 1.08–1,59]; any gout [no CHD]: ARR, 1.32
[95% CI, 1.09–1.60]; any gout [CHD]: ARR, 1.35 [95% CI,
1.19–1.55]) [24].
Compared with the previously reported study results, the
cardiovascular mortality risk determined in the study with
participants in the Taiwanese health-screening program was
higher. The main analysis including gouty patients
corresponding to at least one of the three applied gout
definitions of this study revealed an almost twofold higher
cardiovascular mortality risk in patients with gout compared
with those without the disease (AHR, 1.97 [95% CI,
1.08–3.59]; P00.027). When data were limited to
patients with monosodium urate crystals in the synovial
fluid or corresponding to ICD code 274.x, and excluded
those with self-reported gout, the risk was somewhat
lower (AHR, 1.86 [95% CI, 1.01–3.44]; P00.048) [25￿￿].
All-Cause and Cardiovascular Mortality Risks
in Gouty Subgroups
Different subgroup analyses revealed an independent asso-
ciation between gout and all-cause mortality as well as
cardiovascular mortality not only in the respective study
populations as a whole, but also in several subgroups.
Results for single subgroups are presented accounting for
the impact of comorbidities on the mortality risk.
Sex
Male gouty patients after renal transplantation who were
treated with dialysis had a lower risk of all-cause mortality
than women with the same characteristics (AHR, 1.59 [95%
CI, 1.47–1.71] vs AHR, 1.64 [95% CI, 1.54–1.75]) [21].
Age
The Health Professionals Follow-Up Study revealed an
increased all-cause mortality risk in the population 60 to
69 years of age compared with patients without gout
from the same age group. This mortality risk decreased
as patients grew older. In the youngest age group
(<60 years), the increased mortality risk was not significant
(<60 years: AHR, 1.30 [95% CI, 0.96–1.74]; 60–69 years:
AHR, 1.35 [95% CI, 1.13–1.61]; ≥70 years: AHR, 1.16
[95% CI, 1.01–1.32]). The cardiovascular mortality risk
in patients with gout in the 60- to 69-year subgroup was
more than two times higher than in patients without gout
from the same age group; the risks in the other age
groups were not significantly increased (<60 years: AHR,
1.84 [95% CI, 0.93–3.61]; 60–69 years: AHR, 2.10 [95%
CI, 1.38–3.18]; ≥70 years: AHR, 0.98 [95% CI, 0.68–1.41])
[24]. Thus, gouty patients 60 to 69 years of age seem to be at
elevated all-cause and cardiovascular mortality risk.
Race
The AHR for all-cause mortality was higher in black patients
withgoutthaninother races (AHR, 1.69[95%CI,1.59–1.85]
vs AHR, 1.59 [95% CI, 1.50–1.69]) [21].
Gout Duration
Newly diagnosed gout seems to have a greater impact on
all-cause mortality than established gout (≤5 years: AHR,
1.44; 6–10 years: AHR, 1.37; 11–15 years: AHR, 1.30;
>15 years: AHR, 1.32) [24].
Hypertension
ThemortalityriskingoutypatientsintheHealthProfessionals
Follow-Up Study both with and without hypertension was
almost the same (ARR, 1.24 [95% CI, 1.09–1.41] vs ARR,
1.25 [95% CI, 1.06–1.47]), while subgroup analysis for
cardiovascular mortality did not reveal a significant AHR
in patients with gout [24]. By contrast, dialysis-treated
gouty renal transplant patients with hypertension had a
higher mortality risk than those without hypertension
(AHR, 1.74 [95% CI, 1.55–1.94] vs AHR, 1.59 [95% CI,
1.51–1.68]) [21].
Hypercholesterolemia
Men with gout and hypercholesterolemia have a lower
all-cause mortality risk than those without this comorbidity
(withhypercholesterolemia:ARR,1.15[95%CI,0.96–1.37]vs
without hypercholesterolemia: ARR, 1.30 [95% CI, 1.15–
1.47]) [20]. The influence of hypercholesterolemia did
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gouty patients without hypercholesterolemia seem to
have a higher mortality risk compared with those with
hypercholesterolemia (with hypercholesterolemia: ARR, 1.31
[95% CI, 0.93–1.83] vs without hypercholesterolemia: ARR,
1.55 [95% CI, 1.05–2.30]). Not all results were significant
[24].
Diabetes
Diabetes in patients with gout appears to decrease all-cause
mortality slightly, as the adjusted risk was lower than in
gouty patients without diabetes (AHR, 1.56 [95% CI, 1.44–
1.69] vs AHR, 1.68 [95% CI, 1.58–1.78]) [21].
Discussion
Despite the differences among populations in the studies
included, all multivariate regressions yielded the same
result: There was an independent association between
gout and all-cause mortality as well as cardiovascular
mortality.Conclusionsregardingthecausesofthisassociation
cannot be drawn, as further research would be needed. This
also applies to the question of whether there is an association
between cardiovascular mortality and all-cause mortality.
However, gout elevates the risk of mortality and thus makes
gouty patients an at-risk population.
Patients in whom gout was newly diagnosed after a renal
transplantation had an increased all-cause mortality risk,
whereas this association was not significant in renal
transplant patients with a history of gout [20]. Another
study confirmed the impact of gout on all-cause as well
as cardiovascular mortality in renal transplant patients
treated with dialysis [21]. Furthermore, an independent
association between gout and all-cause mortality as well
as cardiovascular mortality was also found in patients
with any gout or a history of this disorder, irrespective
of CHD comorbidities [24]. Another study confirmed the
association between gout and all-cause mortality in patients
with previous heart failure and acute gout within 60 days
before their death [20]. Gouty patients with hyperuricemia
also had an increased all-cause and cardiovascular mortality
risk [23]. Finally, a study of an Asian population without
specificcomorbiditiesobtainedthesameresult(ie,itindicated
that gout is associated with all-cause as well as cardiovascular
mortality) [25￿￿].
The number of studies evaluating the association between
gout and all-cause or cardiovascular mortality is limited.
More research has been conducted on the questions regarding
whether gout is associated with death from CHD alone
or CVD in general, and the impact of gout on cardio-
vascular events [26–29]. Even these studies indicate
corresponding results: Gout is a risk factor for CVD
a n df o rd e a t hc a u s e db yi t .
The large number of study participants in each of the
studies included strengthens the validity of the results,
although the prevalence of gout in the study population
was somewhat higher than the general estimated prevalence
[2, 6, 7]. Despite the heterogeneous study populations and
differences in gout definition, all studies indicated an
independent association between gout and all-cause as
well as cardiovascular mortality (except for the study
that calculated differences in the mortality rates instead
of ARR/AHR) [19]). That all multivariate regressions
yielded consistent outcomes may be considered another
validation of gout being a risk factor for mortality. More-
over, the specific characteristics of the study population
reflected the typical characteristics of gouty patients:
mainly male, older age, and comorbidities such as CVD
or renal failure.
In spite of the consistent outcomes, the comparability of
the studies is complicated by use of different definitions of
gout. Wijands et al. [30] described the challenge of defining
gout in epidemiologic studies. It is difficult to apply
diagnostic guidelines (eg, monosodium urate crystals),
which are developed for use on an individual level, to
large populations. Drawing on ICD codes might offer a
solution but implies several methodologic uncertainties
[30]. As a consequence, different definitions of a gout
population might entail variant outcomes. This is in line
with the studies analyzed in this review: The mortality
risk varied depending on the gout definition [22￿￿, 23, 25￿￿].
To resolve this challenge, several sensitivity analyses were
conducted.
The impact of patient characteristics and comorbidities
ontheassociationbetweengoutandmortalitywasdetermined
in different subgroup analyses. Regarding race, subgroup
analysis established a higher mortality risk in blacks [21],
which goes hand-in-hand with an increased risk of gout
among this ethnic group. Contrary to the elevated risk of gout
in men described in the literature, one study indicated a
reverse effect, as the risk of all-cause mortality was higher in
women than men [21]. It could be concluded that gout is less
common, but moreserious,inwomen.Furthermore,results of
a subgroup analysis with diabetes, one of the most common
comorbidities in gout, were unexpected. Gouty patients
with diabetes had a slightly lower mortality risk than
those without this comorbidity [21]. One explanation
might be that monitoring is better in patients with diabetes,
although further research is needed to verify this claim. These
results should be interpreted with caution, as they originate
from a study of patients with severe comorbidities (renal
transplant patients treated with dialysis).
The effect of gout duration on the mortality risk was
analyzed in only two studies, both of which reported an
Curr Rheumatol Rep (2012) 14:195–203 201increased mortality risk in patients with new-onset gout and
a slightly lower risk over time [20, 24]. This indicates the
need for early intervention and treatment of gout.
Finally, it should be noted that four of the seven studies
included were explicitly not sponsored by pharmaceutical
companies [19, 21, 22￿￿, 25￿￿], two were partially supported
by the industry [23, 24], and information on sponsorship or
conflict of interest was lacking in one study [20].
Conclusions
Gout is independently associated with all-cause mortality
and cardiovascular mortality. This was the message of six
studies evaluating the association by multivariate regres-
sion. As described, study populations were heterogeneous,
but the study outcomes were nevertheless consistent. The
elevated mortality risk in patients with gout applies to gouty
patients with typical characteristics (black, male, older age)
and classical comorbidities (eg, diabetes, hypertension,
hyperuricemia). Subgroup analyses suggest that patients
with new-onset gout and female sex have a slightly
elevated mortality risk. In addition to these two subgroups,
gouty patients without comorbidities that require regular
monitoring, such as diabetes, might be considered a
vulnerable group. Not only these subgroups, but the
generally increased mortality risk associated with gout
should be borne in mind when treating this disorder. A
need exists for adequate treatment of gout to fulfill the
needs of these at-risk patients.
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